ReviewTranslational gastroenterology and hepatology2018
Management of rectal gastrointestinal stromal tumor.
Review in Translational gastroenterology and hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Local excision and radical excision for rectal gastrointestinal stromal tumors: a meta-analysis protocol.Frontiers in oncology · 2023Pooled it
- Gastrointestinal Stromal Tumours (GIST) of the Rectum: A Systematic Review and Meta-Analysis.Current oncology (Toronto, Ont.) · 2022Pooled it
- A Case Report and Literature Review of a Rectal Gastrointestinal Stromal Tumor.ACG case reports journal · 2026Article
- Paeoniflorin's role in inhibiting malignant metastasis of gastrointestinal stromal tumors via CYP3A4 modulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Endoscopic Full-Thickness Resection of Rectal Gastrointestinal Stromal Tumor With Endoscopic Rectal Reconstruction.ACG case reports journal · 2026Article
- A treatment option for rectal gastrointestinal stromal tumor: endoscopic submucosal dissection combined with endoscopic hand-suturing.Endoscopy · 2025Article
- Transanal minimally invasive surgery for rectal gastrointestinal stromal tumor using articulated forceps after neoadjuvant chemotherapy with imatinib mesylate.International cancer conference journal · 2025Article
- Article
- Article
- Article
- Short-term and long-term outcomes after robotic radical surgery for rectal gastrointestinal stromal tumor.BMC surgery · 2024Article
- Malignant rectal GIST managed with chemotherapy (Imatinib Mesylate): A case report and a comprehensive review.Radiology case reports · 2024Article
- Referral patterns of GIST patients: data from a nationwide study.Acta oncologica (Stockholm, Sweden) · 2024Article
- A Rare Case of a Rectal Gastrointestinal Stromal Tumor (GIST) Discovered During a Routine Colonoscopy.Cureus · 2023Article
- Anal canal gastrointestinal stromal tumour (GIST).BMJ case reports · 2023Article
- Rectal Gastrointestinal Stromal Tumors.Cureus · 2023Article
- A rare rectal gastrointestinal stromal tumor with indolent biological behavior: A case study.Experimental and therapeutic medicine · 2022Article
- A Low rectal GIST.BMJ case reports · 2022Article
- Survival outcome of local vs. radical excision in rectal gastrointestinal stromal tumor: a SEER database analysis.BMC surgery · 2022Article
- Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib.Cancer management and research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. However, rectal GIST is rare, the incident rate of it is approximately 5% of all GISTs. Rectal GIST symptoms generally include bleeding and/or pain and occasionally, urinary symptoms. Immunohistochemical evaluation finds that most rectal GIST tumors are CD117 (KIT) positive, and are sometimes CD34, platelet-derived growth factor receptor alpha (PDGFRA), smooth muscle actin, S-100, or vimentin positive. The National Institutes of Health (NIH) classifies rectal GIST as very-low risk, low risk, intermediate risk, or high risk, and the frequencies have been estimated as 0-23.8% for very-low risk, 0-45% for low risk, 0-34% for intermediate risk, and 21-100% for high risk tumors. The first-line treatment for localized GIST is curative resection, but is difficult in rectal GIST because of anatomical characteristics such as the deep, narrow pelvis and proximity to the sphincter muscle or other organs. Several studies noted the efficacy of the minimally invasive surgery, such as trans-anal, trans-sacral, trans-vaginal resection, or laparoscopic resection. The appropriate surgical procedure should be selected depending on the case. Imatinib mesylate (IM) is indicated as first-line treatment of metastatic or unresectable GIST, and clinical outcomes are correlated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.